Professor Li Chi Kong
CUHK Employment
Professor, Department of Paediatrics, Faculty of Medicine,
The Chinese University of Hong Kong
Phone Number:
+852 3505 2849
Email:
Researcher ID
Research Theme
Biography
Prof. Chi-kong LI graduated from medical school in Hong Kong in 1981. Currently he is Professor at Department of Paediatrics, The Chinese University of Hong Kong, and also honorary consultant at Prince of Wales Hospital and Hong Kong Children’s Hospital. He had been Chief of Service of Department of Paediatrics, Prince of Wales Hospital from 2004 to 2014. Dr. Li is specialized in paediatric haematology, oncology and stem cell transplantation. He is the immediate past Continental President of Asia of International Society of Pediatric Oncology. He is the study chair for acute lymphoblastic leukaemia trials in Hong Kong. He assisted the formation of multicenter clinical trial study groups in China (China Children Leukemia Group, South China Children Cancer Group and the Chinese Children Cancer Group), and had served as the vice-chairman of the CCCG. He is the Hong Kong coordinator of the international clinical research studies: IBFM ALL 2002, Interfant ALL 96 and 2006, EsPhALL study. He has published over 330 peer-reviewed papers, written chapters in 4 books and editor of one book.
Education
Undergraduate medical education at The University of Hong Kong (1976-1981), obtained Doctor of Medicine at The Chinese University of Hong Kong (2002)
Research Interest
Childhood leukaemia, thalassaemia and stem cell transplantation, cellular therapy, palliative care and clinical ethics.
Specialisations
Clinical trials in malignant and non-malignant haematology conditions
Qualification
MBBS, MD, FHKCPaed, FHKAM (Paed), FRCPCH.
Others
- Honorary Professor, Children’s Hospital of Fudan University, West China Second University Hospital, Sichun University, Adjunct Professor, Suzhou University, Suzhou, Visiting Professor, Qilu Children’s Hospital of Shangdong University, Jinan, China
- Editorial member of Chinese Journal of Pediatrics, The Journal of China Pediatric Blood and Cancer, Chinese Journal of Evidence Medicine in Pediatrics, Journal of Xiangya Medicine, Pediatric Investigations (China), Pediatric Hematology Oncology Journal (India), Clinical Pediatric Hematology-Oncology (Korea)
- Professional Service Member, Hospital Authority Hong Kong (2012-2015) Director of Subspecialty Boards, Hong Kong College of Paediatricians (2020- ); Chairman, CUHK-NTEC Clinical Research Management Committee, Medical Advisory Committee, CUHK Medical Centre (April 2020-)
Publication
Selected publications
1. Feng JH, .., Li CK. Double-unit unrelated cord blood transplantation for thalassaemia major: Comparison with HLA-identical sibling bone marrow transplantation. Pediatric Transplantation; 2020; 00:e13901.
2. Feng JH, .., Li CK. Upfront consolidation treatment with 131I-mIBG followed by myeloablative chemotherapy and hematopoietic stem cell transplantation in high-risk neuroblastoma. Pediatric Investigation, 2020; 4(3):168-177, doi.org/10.1002/ped4.12216
3. Suiter CC, .. Li CK, ..M, Yang JJ. Massively parallel variant characterization identifies NUDT15 alleles associated with thiopurine toxicity. Proc Natl Acad Sci U S A. 2020 Feb 24. pii: 201915680. doi: 10.1073/pnas.1915680117.
4. Shen S, .., Li CK, .. Pui CH. Effect of Dasatinib vs Imatinib in the Treatment of Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial. JAMA Oncol. 2020 Jan 16. doi: 10.1001/jamaoncol.2019.5868
5. Zhu Y, .. Li CK. Septicemia after chemotherapy for childhood acute lymphoblastic leukemia in China: A multicenter study CCCG-ALL-2015. Cancer Med, 2020 Jan 28. doi: 10.1002/cam4.2889.
6. Leung KT, .. Li CK. CD9 blockade suppresses disease progression of high-risk pediatric B-cell precursor acute lymphoblastic leukemia and enhances chemosensitivity. Leukemia, 2020; 34:709-720. doi: 10.1038/s41375-019-0593-7.
7. Pieters R, .. Li CK,..Valsecchi MG. Outcome of Infants Younger Than 1 Year With Acute Lymphoblastic Leukemia Treated With the Interfant-06 Protocol: Results From an International Phase III Randomized Study. J Clin Oncol. 2019 Sep 1;37(25):2246-2256. doi: 10.1200/JCO.19.00261. Epub 2019 Jul 8.
8. Biondi A, .. Li CK, ..Grazia Valsecchi M. Imatinib treatment of paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (EsPhALL2010): a prospective, intergroup, open-label, single-arm clinical trial. Lancet Haematol, 2018 Dec;5(12):e641-e652. doi: 10.1016/S2352-3026(18)30173-X.
9. Lund TC, ..Li CK, .., Eapen M. Outcomes After Second Hematopoietic Cell Transplantation in Children and Young Adults with Relapsed Acute Leukemia. Biol Blood Marrow Transplant. 2019, 25:301-306. doi: 10.1016/j.bbmt.2018.09.016.
10. Cui L, .. Li CK, Wu MY; Chinese Children Leukemia Group(CCLG). Outcome of children with newly diagnosed acute lymphoblastic leukemia treated with CCLG-ALL 2008: The first nation-wide prospective multicenter study in China. Am J Hematol. 2018 Jul;93(7):913-920. doi: 10.1002/ajh.25124.